{"product_id":"csl-pestle-analysis","title":"CSL PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political, economic, social, technological, legal and environmental forces are reshaping CSL’s future—insights that inform investment, strategy and risk planning; buy the full PESTLE now for a ready-to-use, deep-dive report you can apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health funding and vaccine procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment budgets and pandemic-preparedness programs directly affect CSL’s influenza demand—the US alone saw about 171.6 million flu vaccine doses distributed in 2022–23, shaping stockpile and procurement plans. Multi-year tenders and BARDA-style bilateral contracts improve volume visibility and pricing power for suppliers. Rising national self-sufficiency and local fill–finish investments can re-route orders from exporters, while post-election policy shifts can rapidly reprioritize immunization versus rare-disease funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlasma collection policy and donor compensation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational rules on donor remuneration and licensing directly affect plasma input; the United States supplies roughly 70% of plasma used for fractionation, while most EU states prohibit paid donation, constraining supply diversity. Such cross-border differences create sourcing and logistics complexity and can tighten or expand availability and margins. Heightened political scrutiny of donor welfare has intensified compliance and monitoring requirements, raising operating costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing and reimbursement politics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrice controls and HTA decisions increasingly constrain CSL pricing power: specialty medicines now represent about 48% of global drug spend (IQVIA 2024), and European HTA QALY thresholds (commonly €20k–€50k) pressure biotherapy valuations. Reference pricing and biosimilar entry have cut prices 30–60% in EU markets, squeezing iron therapy economics. Vaccines largely receive public funding but tender discounts (often 20–80% via Gavi\/UNICEF) compress margins. Statutory rebates and Medicaid-like clawbacks (e.g., US base rebate 23.1% plus inflation penalties) and reimbursement delays can push cash conversion cycles out by months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitics, trade, and supply chain security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExport controls, sanctions and customs delays have disrupted plasma and single-use inputs, pushing some biopharma lead times up by ~20% in 2023–24 and prompting governments to prioritize domestic supplies during health crises (e.g., emergency stockpiles expanded 15–30% in several markets by 2024). Diversification mandates and friend-shoring raise network costs and capex, while political risk insurance and larger inventory buffers are now strategic hedges.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eexport-controls: supply lead times +~20% (2023–24)\u003c\/li\u003e\n\u003cli\u003edomestic-priority: stockpile growth 15–30% (by 2024)\u003c\/li\u003e\n\u003cli\u003efriend-shoring: higher network capex and OPEX\u003c\/li\u003e\n\u003cli\u003emitigants: political-risk insurance, inventory buffers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment and international standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConvergence or divergence among FDA, EMA, TGA and NMPA materially alters trial design and time-to-approval: FDA Priority Review targets six months versus a 10-month standard under PDUFA, EMA central procedures aim for 210 active days, and divergent local data requirements can add months to global launches. Priority review and fast-track schemes (e.g., FDA Accelerated Approval pathways) compress market entry but often impose confirmatory post-market commitments tied to public policy, raising lifecycle costs. Political scrutiny of safety signals can force rapid label changes or usage restrictions, as seen in multiple regulatory actions since 2023 that shifted prescribing and reimbursement decisions within weeks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory timelines: FDA 6m priority \/ 10m standard; EMA 210 active days\u003c\/li\u003e\n\u003cli\u003eFast-track impact: accelerates launch but increases post-market obligations\u003c\/li\u003e\n\u003cli\u003eLifecycle costs: post-market commitments raise compliance spend and trial burden\u003c\/li\u003e\n\u003cli\u003ePolitical risk: safety events can prompt swift label or usage shifts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical shifts drive vaccine procurement volatility, pricing pressure, plasma supply risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts drive demand, procurement and stockpiles (US 171.6M flu doses 2022–23; stockpile growth 15–30% by 2024), reshape pricing via HTA and rebates, and constrain plasma supply (US ~70% of plasma). Export controls raised lead times ~20% (2023–24) and friend-shoring increases capex\/OPEX. Regulatory divergence (FDA 6m priority\/10m standard; EMA ~210 days) speeds launches but raises post-market costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFigure\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlu doses (US)\u003c\/td\u003e\n\u003ctd\u003e171.6M (22–23)\u003c\/td\u003e\n\u003ctd\u003eProcurement volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma share (US)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003eSupply concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead times\u003c\/td\u003e\n\u003ctd\u003e+~20%\u003c\/td\u003e\n\u003ctd\u003eSupply risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eFDA 6m\/10m; EMA 210d\u003c\/td\u003e\n\u003ctd\u003eLaunch timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect CSL across Political, Economic, Social, Technological, Environmental and Legal dimensions, with data-backed, region-specific insights and forward-looking scenario analysis; designed for executives, consultants and investors and delivered in clean, report-ready format to identify threats and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented CSL PESTLE summary that’s easy to drop into presentations, editable for regional or business-line notes, and shareable across teams to quickly align on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic cycles and healthcare budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecessions squeeze payer budgets and can delay elective or non-urgent treatments, even as essential therapies and vaccines remain resilient but encounter tougher price negotiations; US healthcare spending was about 18% of GDP in 2023. Inflation-driven wage, energy and consumable cost increases—US CPI averaged roughly 3.4% in 2024—raise manufacturing and cold-chain expenses. Public budget cycles and tender timing drive stocking patterns and procurement pacing in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX exposure and cost base mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCSL’s predominantly USD\/EUR-denominated global sales against an AUD cost base creates both translation and transaction risk, causing reported margins and capital allocation to vary with FX moves. Multi-region manufacturing and sales provide natural hedges that reduce but do not eliminate exposure. Active hedging programs are used to smooth P\u0026amp;L volatility, at direct financial cost and potential opportunity loss.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlasma supply economics and donor incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDonor compensation (commonly 20-60 USD per plasma donation of ~600-800 mL), center throughput and mandatory screening costs are major contributors to COGS for plasma-derived products. Tight labor markets (US unemployment ~3.7% in 2024) have elevated operating expenses and acquisition cost per liter. Scale efficiencies in fractionation blunt unit costs, but competition for donors intensifies in winter peak seasons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTender dynamics and payer mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSeqirus’ influenza revenues remain highly seasonal and hinge on Northern\/Southern hemisphere tenders versus private markets; winning national tenders drives volume but often compresses ASPs, while private-channel sales preserve margins. Specialty biotherapies rely on reimbursement in high-income markets for uptake, with slower access in emerging markets. CSL Vifor’s nephrology footprint is exposed to dialysis provider contract dynamics following CSL’s acquisition of Vifor completed in 2022.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTender wins = volume, lower price\u003c\/li\u003e\n\u003cli\u003ePrivate markets = higher margin, less volume volatility\u003c\/li\u003e\n\u003cli\u003eBiotherapies need high-income reimbursement for scale\u003c\/li\u003e\n\u003cli\u003eVifor sensitive to dialysis provider contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensity and R\u0026amp;D productivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiologics manufacturing, plasma fractionation plants and fill–finish lines demand sustained capex (fill–finish typically 20–100m, fractionation facilities often 500m+), while industry clinical success from Phase I to approval remains low (~11%), making pipeline success critical to long-term ROI and valuation. Rising cost of capital (pharma WACC ~8–10% in 2024–25) shifts build‑vs‑partner decisions for new modalities; active portfolio pruning reallocates spend to higher NPV assets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapex: fill–finish 20–100m, fractionation 500m+\u003c\/li\u003e\n\u003cli\u003ePipeline success: ~11% Phase I→approval\u003c\/li\u003e\n\u003cli\u003eCost of capital: WACC ~8–10% (2024–25)\u003c\/li\u003e\n\u003cli\u003eStrategy: pruning redirects capital to higher NPV projects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical shifts drive vaccine procurement volatility, pricing pressure, plasma supply risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecessions pressure payer budgets and elective care, while essential therapies\/vaccines remain resilient; US health spend ~18% GDP (2023) and 2024 CPI ~3.4% raise manufacturing and cold‑chain costs. FX exposure from USD\/EUR sales vs AUD base affects margins despite hedging. Plasma donation costs ~20–60 USD\/donation and US unemployment ~3.7% (2024) raise COGS; pharma WACC ~8–10% (2024–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS health spend (2023)\u003c\/td\u003e\n\u003ctd\u003e~18% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI (2024)\u003c\/td\u003e\n\u003ctd\u003e~3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma donation cost\u003c\/td\u003e\n\u003ctd\u003e20–60 USD\/donation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS unemployment (2024)\u003c\/td\u003e\n\u003ctd\u003e~3.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma WACC (2024–25)\u003c\/td\u003e\n\u003ctd\u003e8–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCSL PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview of the CSL PESTLE Analysis shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. The content, layout, and structure are final with no placeholders or teasers. After checkout you’ll instantly download this same professional file, ready for analysis and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162391949689,"sku":"csl-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/csl-pestle-analysis.png?v=1762700138","url":"https:\/\/portersfiveforce.com\/products\/csl-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}